Vifor Pharma Management Ltd (CSL Vifor) formerly Galenica Ltd, focuses on discovery, development, and marketing of prescription medicines and non-prescription drugs. The company offers intravenous pharmaceuticals for iron deficiency, besides products for nephrology and cardio-renal therapies. It also provides pharmaceuticals for the treatment of respiratory tract infections, ear care, abdominal distension, chronic obstructive pulmonary disease, hemorrhoids, chronic venous insufficiency, diabetic retinopathy, lower urinary tract infections, menometrorrhagia, chronic kidney disease, and hyperkalemia. Vifor Pharma also discovers, develops, and markets polymeric medicines for unmet medical needs of the gastrointestinal tract. It operates production plants in Portugal and Switzerland, and carries out business through subsidiaries. Vifor Pharma is headquartered in St. Gallen, Switzerland.
Headquarters
Switzerland
Address
Flughofstrasse 61, Glattbrugg, 8152
Website
www.viforpharma.com
Telephone
41 58 8518000
No of Employees
2,300
Industry
Pharmaceuticals and Healthcare
Revenue (2021)
$1.9B
Vifor Pharma Management Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Iron Products | Ferinject |
| Nephrology Products | Injectafer |
| Cardio Renal Products | Venofer |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Others | In August, the company announced Tavneos (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA). |
| 2022 | New Product Approvals | In April, the company received approval from the European Commission for the use of Kapruvia for the treatment of moderate-to-severe pruritus in hemodialysis patients. |
| 2022 | Regulatory Approval | In February, Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. announced the European Medicines Agency’s (EMA) CHMP approved Kapruvia (difelikefalin) to treat patients with moderate-to-severe pruritus associated with chronic kidney disease in hemodialysis patients. |
Competitor Comparison
| Key Parameters | Vifor Pharma Management Ltd | Johnson & Johnson | Novartis AG | McKesson Europe AG | Stada Arzneimittel AG |
|---|---|---|---|---|---|
| Headquarters | Switzerland | United States of America | Switzerland | Germany | Germany |
| City | Glattbrugg | New Brunswick | Basel | Stuttgart | Bad Vilbel |
| State/Province | - | New Jersey | - | Baden-Wurttemberg | Hessen |
| No. of Employees | 2,300 | 152,700 | 103,000 | 6,808 | 13,183 |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jacques Theurillat | Chairman | Executive Board | 2020 | 63 |
| Abbas Hussain | Chief Executive Officer | Senior Management | 2021 | 57 |
| Alexandros Sigalas | Chief Financial Officer | Senior Management | 2022 | - |
| Christoph Springer, Ph.D. | Chief Strategy Officer | Senior Management | 2018 | 54 |
| Klaus Henning Jensen, M.D. | Chief Medical Officer | Senior Management | 2020 | 49 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward